The biotech firm reported a Q1 GAAP loss of $0.14 per share and $0.23M in revenue, both exceeding analyst expectations.
ProKidney reported a first-quarter GAAP loss of $0.14 per share, narrower than the expected loss by $0.01. Revenue reached $0.23M, beating estimates by $0.03M but remaining flat year-over-year.
Cash reserves totaled $224.9 million as of March 31, 2026, down from $270.0 million at the end of 2025. The company stated its current liquidity will fund operations into mid-2027.